| Title: |
mRNA Degradation as a Therapeutic Solution for Mucopolysaccharidosis Type IIIC: Use of Antisense Oligonucleotides to Promote Downregulation of Heparan Sulfate Synthesis. |
| Authors: |
Santos, Juliana Inês1,2,3,4 (AUTHOR) mprata@ipatimup.pt, Gonçalves, Mariana1,2,3,5 (AUTHOR) mariana.goncalves@insa.min-saude.pt, Almeida, Matilde Barbosa1,2,3,6 (AUTHOR) matilde.almeida@insa.min-saude.pt, Rocha, Hugo7 (AUTHOR) hugo.rocha@insa.min-saude.pt, Duarte, Ana Joana1,2,3,8 (AUTHOR) ana.duarte@insa.min-saude.pt, Matos, Liliana1,2,3 (AUTHOR) liliana.matos@insa.min-saude.pt, Moreira, Luciana Vaz1,2,3 (AUTHOR) luciana.moreira@insa.min-saude.pt, Encarnação, Marisa1,2,3 (AUTHOR) marisa.encarnacao@insa.min-saude.pt, Gaspar, Paulo7 (AUTHOR) paulo.gaspar@insa.min-saude.pt, Prata, Maria João4,9 (AUTHOR), Coutinho, Maria Francisca1,2,3 (AUTHOR) francisca.coutinho@insa.min-saude.pt, Alves, Sandra1,2,3 (AUTHOR) sandra.alves@insa.min-saude.pt |
| Source: |
International Journal of Molecular Sciences. Feb2025, Vol. 26 Issue 3, p1273. 16p. |
| Subject Terms: |
*MOLECULES, *SANFILIPPO syndrome, *HEPARAN sulfate, *LYSOSOMAL storage diseases, *ANTISENSE RNA, *OLIGONUCLEOTIDES |
| Abstract: |
Mucopolysaccharidosis type IIIC is a neurodegenerative lysosomal storage disorder (LSD) characterized by the accumulation of undegraded heparan sulfate (HS) due to the lack of an enzyme responsible for its degradation: acetyl-CoA:α-glucosaminide N-acetyltransferase (HGSNAT). Classical treatments are ineffective. Here, we attempt a new approach in genetic medicine, genetic substrate reduction therapy (gSRT), to counteract this neurological disorder. Briefly, we used synthetic oligonucleotides, particularly gapmer antisense oligonucleotides (ASOs), to target the synthesis of the accumulated compounds at the molecular level, downregulating a specific gene involved in the first step of HS biosynthesis, XYLT1. Our goal was to reduce HS production and, consequently, its accumulation. Initially, five gapmer ASOs were designed and their potential to decrease XYLT1 mRNA levels were tested in patient-derived fibroblasts. Subsequent analyses focused on the two best performing molecules alone. The results showed a high inhibition of the XYLT1 gene mRNA (around 90%), a decrease in xylosyltransferase I (XT-I) protein levels and a reduction in HS storage 6 and 10 days after transfection (up to 21% and 32%, respectively). Overall, our results are highly promising and may represent the initial step towards the development of a potential therapeutic option not only for MPS IIIC, but virtually for every other MPS III form. Ultimately, the same principle may also apply to other neuropathic MPS. [ABSTRACT FROM AUTHOR] |
|
Copyright of International Journal of Molecular Sciences is the property of MDPI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Academic Search Complete |
|
Full text is not displayed to guests. |
Login for full access.
|
